1.09

0.91% -0.01

Cytomx Therapeutics Inc (CTMX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.10

Offen:

$1.06

24-Stunden-Volumen:

967.05K

Relative Volume:

0.86

Marktkapitalisierung:

$85.30M

Einnahmen:

$101.21M

Nettoeinkommen (Verlust:

$-569.00K

KGV:

-1.2976

EPS:

-0.84

Netto-Cashflow:

$-56.88M

1W Leistung:

-1.80%

1M Leistung:

+25.27%

6M Leistung:

-14.84%

1J Leistung:

-18.66%

1-Tages-Spanne:

$1.03

$1.10

1-Wochen-Bereich:

$1.00

$1.16

52-Wochen-Spanne:

$0.833

$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Firmenname

Cytomx Therapeutics Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

650.515.3185

Adresse

151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA

Mitarbeiter

122

Twitter

@cytomxinc

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

CTMX's Discussions on Twitter

Vergleichen Sie CTMX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CTMX Cytomx Therapeutics Inc	1.09	85.30M	101.21M	-569.00K	-56.88M	-0.02
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-05-28	Hochstufung	Piper Sandler	Neutral → Overweight
2024-05-09	Hochstufung	Wedbush	Neutral → Outperform
2024-05-06	Hochstufung	Jefferies	Hold → Buy
2024-04-22	Hochstufung	JP Morgan	Underweight → Neutral
2022-11-14	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2022-07-07	Herabstufung	Jefferies	Buy → Hold
2022-07-07	Herabstufung	Mizuho	Buy → Neutral
2022-07-07	Herabstufung	Piper Sandler	Overweight → Neutral
2022-07-07	Herabstufung	Wedbush	Outperform → Neutral
2022-06-24	Eingeleitet	BMO Capital Markets	Outperform
2022-01-18	Hochstufung	Barclays	Underweight → Overweight
2021-11-15	Eingeleitet	BTIG Research	Buy
2021-05-28	Herabstufung	Barclays	Equal Weight → Underweight
2021-03-29	Eingeleitet	JP Morgan	Overweight
2021-03-23	Hochstufung	Jefferies	Hold → Buy
2020-09-22	Herabstufung	Guggenheim	Buy → Neutral
2020-06-01	Herabstufung	Jefferies	Buy → Hold
2020-05-14	Bestätigt	H.C. Wainwright	Buy
2020-03-24	Hochstufung	Wedbush	Neutral → Outperform
2020-03-04	Eingeleitet	Barclays	Equal Weight
2019-11-20	Eingeleitet	Guggenheim	Buy
2019-11-11	Herabstufung	Wedbush	Outperform → Neutral
2019-06-13	Eingeleitet	Mizuho	Buy
2019-05-14	Eingeleitet	Cantor Fitzgerald	Overweight
2019-03-11	Eingeleitet	Barclays	Overweight
2018-11-26	Eingeleitet	Piper Jaffray	Overweight
2018-10-15	Eingeleitet	Goldman	Neutral
2018-09-13	Eingeleitet	H.C. Wainwright	Buy
2018-06-01	Eingeleitet	SunTrust	Buy
2018-01-05	Eingeleitet	Citigroup	Buy
2017-09-08	Eingeleitet	Wedbush	Outperform
2017-03-27	Eingeleitet	H.C. Wainwright	Buy
2017-03-02	Eingeleitet	Instinet	Buy
2017-01-03	Herabstufung	Oppenheimer	Outperform → Perform
2015-11-02	Eingeleitet	Oppenheimer	Outperform

Alle ansehen

Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten

03:13 AM

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Position Raised by Fmr LLC - Defense World

03:13 AM

Dec 20, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 20, 2024

Dec 18, 2024

CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat

Dec 18, 2024

SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS - MSN

Dec 18, 2024

Dec 17, 2024

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry - Simply Wall St

Dec 17, 2024

Dec 16, 2024

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Dec 16, 2024

Dec 13, 2024

CytomX Therapeutics' SWOT analysis: biotech stock's solid tumor focus By Investing.com - Investing.com Canada

Dec 13, 2024

Dec 10, 2024

Janus Henderson Group PLC Trims Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - MarketBeat

Dec 10, 2024

Dec 06, 2024

Recent uptick might appease CytomX Therapeutics, Inc. (NASDAQ:CTMX) institutional owners after losing 21% over the past year - Simply Wall St

Dec 06, 2024

Nov 30, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 21.7% in November - MarketBeat

Nov 30, 2024

Nov 28, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Brokerages - Defense World

Nov 28, 2024

Nov 27, 2024

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - The Manila Times

Nov 27, 2024

Nov 25, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Analysts - MarketBeat

Nov 25, 2024

Nov 19, 2024

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround - Yahoo Finance

Nov 19, 2024

Nov 15, 2024

CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com India

Nov 15, 2024

Biotechnology Value Fund L P Increases Stake in CytomX Therapeutics Inc - GuruFocus.com

Nov 15, 2024

TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com

Nov 14, 2024

HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World

Nov 14, 2024

Nov 13, 2024

HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat

Nov 13, 2024

Nov 12, 2024

CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK

Nov 12, 2024

Nov 11, 2024

CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 11, 2024

Nov 09, 2024

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat

Nov 09, 2024

Nov 08, 2024

CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia

Nov 08, 2024

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN

Nov 08, 2024